Roche’s Q2 sales growth of 6% at CER (+4% in Q1) was largely driven by pharma (+7% to CHF10.2bn), while the Diagnostics business was slower at 4% growth to CHF3.1bn (vs +6% in Q1, +5% in Q4 16, +8% in Q3 16 and +8% in Q2 16). H1 scored a CER 5% growth at the group level, implying 5% growth each in the Pharma and the Diagnostics businesses. NB all sales growth numbers are in CER, unless mentioned otherwise. Nearly half of the pharma’s H1 growth came from the strongly trending new p
13 Sep 2017
Strong Ocrevus launch discredited by R&D glitches
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Ocrevus launch discredited by R&D glitches
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
13 Sep 2017 -
Author:
Kamla Singh -
Pages:
4
Roche’s Q2 sales growth of 6% at CER (+4% in Q1) was largely driven by pharma (+7% to CHF10.2bn), while the Diagnostics business was slower at 4% growth to CHF3.1bn (vs +6% in Q1, +5% in Q4 16, +8% in Q3 16 and +8% in Q2 16). H1 scored a CER 5% growth at the group level, implying 5% growth each in the Pharma and the Diagnostics businesses. NB all sales growth numbers are in CER, unless mentioned otherwise. Nearly half of the pharma’s H1 growth came from the strongly trending new p